Skip to main content

Table 2 Association of ROR1 with: TTF-1 expression; EGFR, KRAS mutations by median and cut-off

From: Functional and clinical significance of ROR1 in lung adenocarcinoma

Overall population

ROR1 expression

≤ median

>median

p value

cut-off ≤1

cut-off > 1

p value

EGFR

wt

25

26

0.7027

37

14

0.5569

mut

2

3

3

2

KRAS

wt

14

16

0.8051

20

10

0.4011

mut

13

13

20

6

TTF-1

neg

6

5

0.6422

8

3

0.9161

pos

21

24

32

13

Localized disease

ROR1 expression

≤ median

>median

p value

cut-off ≤1

cut-off > 1

p value

EGFR

wt

24

23

0.6413

34

13

0.5663

mut

2

3

3

2

KRAS

wt

13

14

0.7834

17

10

0.1797

mut

13

12

20

5

TTF-1

neg

6

5

0.7367

8

3

0.8978

pos

20

21

29

12

Advanced disease

ROR1 expression

≤ median

>median

p value

cut-off ≤1

cut-off > 1

p value

EGFR

wt

1

3

0

3

1

0

mut

0

0

0

0

KRAS

wt

1

2

0.5637

3

0

0.0833

mut

0

1

0

1

TTF-1

neg

0

0

0

0

0

0

pos

1

3

3

1

  1. Statistical evaluation of ROR1 expression distribution, estimated by the median and the cut-off (equal to 1), among the analyzed molecular markers: EGFR, KRAS mutations; TTF-1 expression. The p values results and the severity of the disease are reported in bold